The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
10X Genomics, Inc. CLASS A COMMON 88025U109 342,870 2,750,000 SH   SOLE   2,750,000 0 0
Acceleron Pharma Inc. COM 00434H108 2,149 19,100 SH   SOLE   19,100 0 0
Epizyme, Inc. COM 29428V104 2,908 243,759 SH   SOLE   243,759 0 0
Novavax, Inc. COM 670002401 7,239 66,810 SH   SOLE   66,810 0 0